Shares of Fisher & Paykel Healthcare Co. Limited (OTCMKTS:FSPKF – Get Free Report) traded up 8.8% on Wednesday. The stock traded as high as $28.09 and last traded at $28.09. Approximately 294 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 3,061 shares. The stock had previously closed at $25.8150.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada raised shares of Fisher & Paykel Healthcare from a “sector perform” rating to an “outperform” rating in a report on Tuesday, September 15th. Citigroup upgraded shares of Fisher & Paykel Healthcare to a “buy” rating in a report on Thursday, September 10th. Two investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Fisher & Paykel Healthcare currently has a consensus rating of “Buy”.
View Our Latest Stock Analysis on Fisher & Paykel Healthcare
Fisher & Paykel Healthcare Stock Performance
The business has a 50 day simple moving average of $25.95 and a two-hundred day simple moving average of $23.65.
Fisher & Paykel Healthcare Company Profile
Fisher & Paykel Healthcare Corporation Limited is a New Zealand-based medical device company that develops, manufactures and markets products used in respiratory care, acute care and the treatment of obstructive sleep apnea. Its technologies are designed to support breathing, improve patient comfort and help healthcare professionals deliver respiratory therapies in hospitals, clinics and the home.
The company’s product portfolio includes respiratory humidification systems, heated breathing circuits, nasal high-flow therapy products, anesthesia and operating-room equipment, neonatal respiratory care products, and masks and related systems for sleep apnea treatment.
Further Reading
- Five stocks we like better than Fisher & Paykel Healthcare
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Fisher & Paykel Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fisher & Paykel Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
